Vaxcyte/ US92243G1085 /
| 2024-04-19 7:30:21 PM | Chg. -0.66 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 59.99USD | -1.09% | 23,194 Turnover: 1.41 mill. |
-Bid Size: - | -Ask Size: - | 61.88 | 59.69 |
GlobeNewswire
04-02
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid t...
GlobeNewswire
03-25
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated...
GlobeNewswire
03-04
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneum...
GlobeNewswire
02-27
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
02-15
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
GlobeNewswire
02-03
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’...
GlobeNewswire
02-01
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
GlobeNewswire
01-30
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire
01-29
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pne...
GlobeNewswire
01-04
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC
GlobeNewswire
01-04
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Con...
GlobeNewswire
2023-12-18
Enterome Appoints Industry Veteran Dr. Peter Hirth to its Board of Directors
GlobeNewswire
2023-12-14
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta...
GlobeNewswire
2023-12-11
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (lu...
GlobeNewswire
2023-12-05
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight B...
GlobeNewswire
2023-11-27
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obta...
GlobeNewswire
2023-11-21
Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
GlobeNewswire
2023-11-13
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticip...
GlobeNewswire
2023-11-09
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of...
GlobeNewswire
2023-11-06
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
